News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

December 8, 2015

Kyowa Medex Launched "Liaison 25 -hydroxyvitamin D Total" in Japan

Tokyo, Japan, December 8, 2015 --- Kyowa Medex Co., Ltd. (President & CEO; Masahito Yamaguchi, "Kyowa Medex") announced today that it has launched an in vitro diagnostic (IVD) reagents, "Liaison 25-hydroxyvitamin D Total".

"Liaison 25-hydroxyvitamin D Total" is a DiaSorin S.p.A's product which was registered as an IVD on April 6, 2015, by Kyowa Medex in Japan. The clinical indication of this product is to help diagnose the vitamin D deficient status among patients by measuring the total concentration of serum 25-hydroxyvitamin D2 and D3. (submitted for National Health Insurance points acquisition from Japanese government)

"Liaison 25-hydroxyvitamin D Total" works on the fully automated chemiluminescence analyzer, Liaison XL (released on July 7, 2015) and produces accurate measurement results of the combined concentration of serum 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 with high efficiency. The obtained results can be employed to help diagnose vitamin D deficiency status of patients accurately.

Kyowa Medex is working to support treatment for a wide range of diseases and contribute to the improvement of patients' QOL through the development of IVD reagents and medical devices that meet the current clinical needs in addition to conventional biochemistry reagents and immunoassay reagents and measurement devices, which are its current major products.

About DiaSorin S.p.A
DiaSorin S.p.A is a worldwide developer, manufacturer, and marketer of IVDs, headquartered in Saluggia, VC, Italy, and listed in the FTSE Mid Cap Index (the consolidated revenue for 2014 was 443.8 million euros). The current CEO is Dr. Carlo Rosa. For additional information, please refer to the company' website:New window opens
Kyowa Medex and DiaSorin S.p.A have been in business relationship since 2006.

About Vitamin Deficiency
Vitamin D is an essential, trace nutrient taking the forms of Vitamin D2 and D3, which can be taken from mushrooms and fatty fishes, respectively. Furthermore, Vitamin D levels can be increased by spending time in the sun. Vitamin D2 and D3 are converted into 25-hydroxyvitamin D2 and D3 and circulate in blood stably. The total concentration of these metabolites are known as the most reliable marker to assess one's Vitamin D sufficiency status. Vitamin D deficiency, which literally means Vitamin D deficient status in human, causes nutritional rickets among children, osteomalacia among adults, hypocalcemia in all ages. Serum 25-hydroxyvitamin's concentration measurement is considered to be effective in identification of true cause of these illnesses.

About Kyowa Medex
Kyowa Medex Co., Ltd. (ISO 9001 certified, Tokyo, Japan), wholly owned subsidiary of Kyowa Hakko Kirin, was founded in 1981 taking over the parent company's operation related to diagnostic reagent. Kyowa Medex has been focusing on developing, manufacturing and marketing of clinical diagnostic reagents (immunological and biochemical) and medical devices. Based upon its accumulated biotechnological expertise, Kyowa Medex is working on support for expansion of clinical laboratory medicine through developing and improving, for example, a series of assay reagent named as "Determiner" for a HDL cholesterol direct measurement as well as other lipid analysis, which are first launched in the world.

To Page Top